Your browser doesn't support javascript.
loading
Repositioning Drugs for Rare Diseases Based on Biological Features and Computational Approaches.
Otero-Carrasco, Belén; Prieto Santamaría, Lucía; Ugarte Carro, Esther; Caraça-Valente Hernández, Juan Pedro; Rodríguez-González, Alejandro.
Afiliação
  • Otero-Carrasco B; Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain.
  • Prieto Santamaría L; ETS Ingenieros Informáticos, Universidad Politécnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain.
  • Ugarte Carro E; Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain.
  • Caraça-Valente Hernández JP; ETS Ingenieros Informáticos, Universidad Politécnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain.
  • Rodríguez-González A; Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain.
Healthcare (Basel) ; 10(9)2022 Sep 16.
Article em En | MEDLINE | ID: mdl-36141396
Rare diseases are a group of uncommon diseases in the world population. To date, about 7000 rare diseases have been documented. However, most of them do not have a known treatment. As a result of the relatively low demand for their treatments caused by their scarce prevalence, the pharmaceutical industry has not sufficiently encouraged the research to develop drugs to treat them. This work aims to analyse potential drug-repositioning strategies for this kind of disease. Drug repositioning seeks to find new uses for existing drugs. In this context, it seeks to discover if rare diseases could be treated with medicines previously indicated to heal other diseases. Our approaches tackle the problem by employing computational methods that calculate similarities between rare and non-rare diseases, considering biological features such as genes, proteins, and symptoms. Drug candidates for repositioning will be checked against clinical trials found in the scientific literature. In this study, 13 different rare diseases have been selected for which potential drugs could be repositioned. By verifying these drugs in the scientific literature, successful cases were found for 75% of the rare diseases studied. The genetic associations and phenotypical features of the rare diseases were examined. In addition, the verified drugs were classified according to the anatomical therapeutic chemical (ATC) code to highlight the types with a higher predisposition to be repositioned. These promising results open the door for further research in this field of study.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Healthcare (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Healthcare (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha País de publicação: Suíça